Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
616.18
+4.84 (0.79%)
Jun 9, 2026, 4:00 PM EDT - Market closed
Regeneron Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 14,920 | 14,343 | 14,202 | 13,117 | 12,173 | 16,072 | |
Revenue Growth (YoY) | 5.92% | 0.99% | 8.27% | 7.76% | -24.26% | 89.14% |
Cost of Revenue | 2,306 | 2,101 | 1,971 | 1,816 | 1,560 | 2,438 |
Gross Profit | 12,614 | 12,242 | 12,232 | 11,301 | 10,613 | 13,634 |
Selling, General & Admin | 2,715 | 2,700 | 2,954 | 2,631 | 2,116 | 1,825 |
Research & Development | 6,280 | 5,974 | 5,233 | 4,625 | 3,848 | 2,908 |
Other Operating Expenses | -10 | -10 | 53.4 | -2.1 | -89.9 | -45.6 |
Total Operating Expenses | 8,985 | 8,664 | 8,241 | 7,254 | 5,874 | 4,687 |
Operating Income | 3,629 | 3,578 | 3,991 | 4,047 | 4,739 | 8,947 |
Interest Expense | -48 | -43.8 | -55.2 | -73 | -59.4 | -57.3 |
Other Non-Operating Income (Expense) | 1,576 | 1,697 | 844.4 | 225.2 | 179.3 | 436.3 |
Total Non-Operating Income (Expense) | 1,528 | 1,653 | 789.2 | 152.2 | 119.9 | 379 |
Pretax Income | 5,157 | 5,231 | 4,780 | 4,199 | 4,859 | 9,326 |
Provision for Income Taxes | 733.5 | 725.8 | 367.3 | 245.7 | 520.4 | 1,251 |
Net Income | 4,423 | 4,505 | 4,413 | 3,954 | 4,338 | 8,075 |
Net Income to Common | 4,423 | 4,505 | 4,413 | 3,954 | 4,338 | 8,075 |
Net Income Growth | -1.69% | 2.09% | 11.61% | -8.87% | -46.28% | 129.86% |
Shares Outstanding (Basic) | 104 | 105 | 108 | 107 | 107 | 106 |
Shares Outstanding (Diluted) | 108 | 109 | 115 | 114 | 114 | 112 |
Shares Change (YoY) | -5.61% | -5.65% | 1.23% | 0.18% | 1.16% | -2.52% |
EPS (Basic) | 42.53 | 43.07 | 40.90 | 37.05 | 40.51 | 76.40 |
EPS (Diluted) | 41.04 | 41.48 | 38.34 | 34.77 | 38.22 | 71.97 |
EPS Growth | 4.48% | 8.19% | 10.27% | -9.03% | -46.89% | 135.81% |
Shares Outstanding | 105 | 105.7 | 109.6 | 109.4 | 109.6 | 108.68 |
Free Cash Flow | 4,113 | 4,081 | 3,665 | 3,875 | 4,425 | 6,529 |
Free Cash Flow Growth | 0.80% | 11.35% | -5.44% | -12.42% | -32.23% | 225.90% |
Free Cash Flow Per Share | 38.17 | 37.57 | 31.84 | 34.08 | 38.98 | 58.19 |
Dividends Per Share | 3.580 | 3.520 | - | - | - | - |
Dividend Growth | 1.70% | - | - | - | - | - |
Gross Margin | 84.55% | 85.35% | 86.13% | 86.16% | 87.18% | 84.83% |
Operating Margin | 24.32% | 24.95% | 28.10% | 30.85% | 38.93% | 55.67% |
Profit Margin | 29.65% | 31.41% | 31.07% | 30.14% | 35.64% | 50.25% |
FCF Margin | 27.57% | 28.45% | 25.80% | 29.54% | 36.35% | 40.63% |
EBITDA | 4,169 | 4,122 | 4,474 | 4,468 | 5,080 | 9,233 |
EBITDA Margin | 27.94% | 28.74% | 31.50% | 34.06% | 41.73% | 57.45% |
EBIT | 3,629 | 3,578 | 3,991 | 4,047 | 4,739 | 8,947 |
EBIT Margin | 24.32% | 24.95% | 28.10% | 30.85% | 38.93% | 55.67% |
Effective Tax Rate | 14.22% | 13.88% | 7.68% | 5.85% | 10.71% | 13.41% |